The study also showed that participants felt the share of cost covered by the state was not high enough when it comes to the cost of cancer.
Einnig töldu þátttakendur að kostnaðarhlutur ríkisins væri ekki nægilega hár þegar kemur að kostnaði vegna krabbameins.